siRNA-based therapeutic candidate targeting PRDM2 for inhibition of lung cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Lung cancer is a leading cause of cancer-related mortality globally.
• The PRDM2 gene, encoding RIZ1 and RIZ2, is often dysregulated in lung cancer, with RIZ2 overexpression promoting tumor progression.
• Targeting oncogenic RIZ2 presents a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy of ARIZ-047, a siRNA targeting the oncogenic RIZ2 isoform, as a potential lung cancer therapy.
• To investigate the effects of RIZ2 inhibition on lung cancer cell viability, gene expression, and tumor growth.
• To explore the role of the Wnt signaling pathway in RIZ2-mediated lung cancer progression.

Main Methods:

• Utilized ARIZ-047, a small interfering RNA (siRNA), to selectively inhibit RIZ2 expression in lung cancer cells.
• Performed transcriptomic analysis to assess gene expression changes following ARIZ-047 treatment.
• Evaluated the in vivo efficacy of ARIZ-047 encapsulated in targeted nanoparticles (T-CaP) in a lung cancer xenograft mouse model.

Main Results:

• ARIZ-047 treatment led to increased RIZ1 expression and decreased viability in the A549 lung cancer cell line.
• Transcriptomic analysis revealed modulation of the Wnt signaling pathway and downregulation of proliferation and metastasis-associated genes.
• In vivo studies demonstrated significant tumor size reduction and decreased RIZ2 expression in xenograft models treated with T-CaP encapsulated ARIZ-047.

Conclusions:

• ARIZ-047 demonstrates potential as a targeted therapy for lung cancer by selectively inhibiting oncogenic RIZ2.
• The study suggests that the Wnt signaling pathway is implicated in RIZ2 overexpression and lung cancer progression.
• Targeted delivery of ARIZ-047 using nanoparticles enhances its therapeutic efficacy in vivo.